AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3548209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin (Group A)
Number of subjects: 38
Study 3548209 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg PGE2 as a vaginal suppository (Group B)
Number of subjects: 38
Study 3548209 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 38
Study 3548209 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 38
Study 29132805 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE probe
Number of subjects: 100
Study 29132805 — intervention group
Group type: COMPARATOR
Intervention: Vascular probe
Number of subjects: 100
Study 26885782 — intervention group
Group type: EXPERIMENTAL
Intervention: DFD-01
Number of subjects: 351
Study 26885782 — intervention group
Group type: COMPARATOR
Intervention: Diprolene
Number of subjects: 351
Study 26885782 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 351
Study 24344086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 2589
Study 24344086 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2589
Study 24344086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 2589
Study 22143619 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias cash transfer program
Number of subjects: 2073
Study 22143619 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2073
Study 22143619 — intervention group
Group type: EXPERIMENTAL
Intervention: Household wealth
Number of subjects: 2073
Study 19875087 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib 0.3 mg
Number of subjects: 20
Study 19875087 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib 1 mg
Number of subjects: 20
Study 17620136 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoralis minor length test
Number of subjects: 90
Study 16181934 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (19.6g/d)
Number of subjects: 40
Study 16181934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11939381 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary health care liaison worker (PHCLW) services
Number of subjects: 155
Study 11939381 — intervention group
Group type: COMPARATOR
Intervention: Standard support from the community drug team (CDT)
Number of subjects: 155
Study 10516703 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone (1500 mg daily from transplant day -5 to day -1, then 3 days per week until day +100)
Number of subjects: 39
Study 10516703 — intervention group
Group type: COMPARATOR
Intervention: TMP/SMX (160/800 mg daily from transplant day -5 to day -1, then 3 days per week until day +100)
Number of subjects: 39
Study 7726804 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural group treatment
Number of subjects: 24
Study 7726804 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 24
Study 2402122 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaCl infusion (6 mEq per kg body wt for 120 minutes)
Number of subjects: 10
Study 2402122 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaCl infusion (6 mEq per kg body wt for 120 minutes)
Number of subjects: 10
Study 2402122 — intervention group
Group type: COMPARATOR
Intervention: 5% NaCl infusion
Number of subjects: 10
Study 2402122 — intervention group
Group type: COMPARATOR
Intervention: Desoxycorticosterone acetate (DOCA; 20 mg i.m. for three days) before saline (5%) infusion
Number of subjects: 10
Study 31997794 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma therapy with total contact casting (Group A)
Number of subjects: 118
Study 31997794 — intervention group
Group type: COMPARATOR
Intervention: Total contact casting alone (Group B)
Number of subjects: 118
Study 31997794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 118
Study 31997794 — intervention group
Group type: EXPERIMENTAL
Intervention: Paucibacillary leprosy patients
Number of subjects: 118
Study 31997794 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lower initial surface area of the ulcer
Number of subjects: 118
Study 30940833 — intervention group
Group type: EXPERIMENTAL
Intervention: FOS at 2.5 g/day
Number of subjects: 80
Study 30940833 — intervention group
Group type: EXPERIMENTAL
Intervention: FOS at 5 g/day
Number of subjects: 80
Study 30940833 — intervention group
Group type: EXPERIMENTAL
Intervention: FOS at 10 g/day
Number of subjects: 80
Study 30940833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Maltodextrin 10 g/day)
Number of subjects: 80
Study 30940833 — intervention group
Group type: EXPERIMENTAL
Intervention: FOS (all doses)
Number of subjects: 80
Study 27910708 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol (2 g twice a day)
Number of subjects: 40
Study 27910708 — intervention group
Group type: COMPARATOR
Intervention: Myo-inositol (2 g/d) plus melatonin (3 g/d before sleeping)
Number of subjects: 40
Study 26121625 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Follow-up (RF)
Number of subjects: 83
Study 26121625 — intervention group
Group type: COMPARATOR
Intervention: Hospital Follow-up (HF)
Number of subjects: 83
Study 22419416 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy levels in the top three quintiles
Number of subjects: 221
Study 22448804 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive emotion regulation group therapy (ERGT) for 14 weeks
Number of subjects: 23
Study 22448804 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive emotion regulation group therapy (ERGT)
Number of subjects: 23
Study 19268732 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 314
Study 19268732 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban
Number of subjects: 314
Study 17206289 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (0.5 million KIU infused before and during cardiopulmonary bypass)
Number of subjects: 162
Study 17206289 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 ml normal saline infused before and during cardiopulmonary bypass)
Number of subjects: 162
Study 17206289 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 162
Study 15742795 — intervention group
Group type: EXPERIMENTAL
Intervention: Child behavior problems
Number of subjects: 69
Study 11555157 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole and/or Chinese medicinal herbs
Number of subjects: 43
Study 11555157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with levamisole plus Chinese medicinal herbs
Number of subjects: 43
Study 11555157 — intervention group
Group type: COMPARATOR
Intervention: Levamisole only
Number of subjects: 43
Study 11555157 — intervention group
Group type: COMPARATOR
Intervention: Chinese medicinal herbs only
Number of subjects: 43
Study 11555157 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 43
Study 9661860 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.0625‐0.25%)
Number of subjects: 87
Study 9661860 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.0625‐0.25%) + Fentanyl (2‐10 micrograms)
Number of subjects: 87
Study 9661860 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Bupivacaine and Bupivacaine + Fentanyl)
Number of subjects: 87
Study 7923458 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 to 90 mg/day
Number of subjects: 126
Study 7923458 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa 750 to 2000 mg/day
Number of subjects: 126
Study 3044642 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group
Number of subjects: 68
Study 3044642 — intervention group
Group type: COMPARATOR
Intervention: Medical group
Number of subjects: 68
Study 30130297 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo cream with information that it would reduce pain
Number of subjects: 296
Study 30130297 — intervention group
Group type: COMPARATOR
Intervention: Natural history group receiving pain stimuli without any application of cream or manipulation of expectation
Number of subjects: 296
Study 28202745 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 22
Study 28202745 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (ETN)
Number of subjects: 22
Study 25513971 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive training (MCT)
Number of subjects: 80
Study 25513971 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 80
Study 23553549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion 150 mEq/L in 5% dextrose solution
Number of subjects: 92
Study 23553549 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride 154 mEq/L infusion
Number of subjects: 92
Study 23553549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion
Number of subjects: 92
Study 23553549 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride infusion
Number of subjects: 92
Study 20090541 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg kg(‐1) hydroxyzine hydrochloride suspension (Atarax) 1 h preoperatively (group I, n=15)
Number of subjects: 60
Study 20090541 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 mg kg(‐1) midazolam (Dormicum) 15 min preoperatively (group II, n=15)
Number of subjects: 60
Study 20090541 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg kg(‐1) ketamine (Ketalar) with 0.25 mg kg(‐1) midazolam (Dormicum) 15 min preoperatively (group III, n=15)
Number of subjects: 60
Study 20090541 — intervention group
Group type: COMPARATOR
Intervention: No oral premedication administration (group IV, controls, n=15)
Number of subjects: 60
Study 19047540 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher training in classroom instruction and management, child social and emotional skill development, and parent workshops
Number of subjects: 598
Study 19047540 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 598
Study 17180512 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT) with weekly carboplatin or low daily dose of cisplatin
Number of subjects: 63
Study 17180512 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage surgery after CRT
Number of subjects: 63
Study 17180512 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 63
Study 17180512 — intervention group
Group type: COMPARATOR
Intervention: Neck dissection (ND) after CRT
Number of subjects: 63
Study 14649345 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 80 microg kg min infusion
Number of subjects: 60
Study 14649345 — intervention group
Group type: COMPARATOR
Intervention: Saline (control) infusion
Number of subjects: 60
Study 11324989 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Number of subjects: 58
Study 11324989 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine
Number of subjects: 58
Study 11324989 — intervention group
Group type: EXPERIMENTAL
Intervention: selegiline
Number of subjects: 58
Study 11324989 — intervention group
Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 58
Study 8780077 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 74
Study 8780077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 1395210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular arrhythmias in CHF patients, including ambient ventricular premature complexes and nonsustained ventricular tachycardia on a 24‐h Holter recording.
Number of subjects: 0
Study 1395210 — intervention group
Group type: EXPERIMENTAL
Intervention: Low left ventricular ejection fraction (LVEF) predicting inducible sustained ventricular tachycardia on electrophysiologic study.
Number of subjects: 0
Study 1395210 — intervention group
Group type: EXPERIMENTAL
Intervention: New York Heart Association (NYHA) Functional Class worsening.
Number of subjects: 0
Study 1395210 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall yearly mortality in CHF patients.
Number of subjects: 0
Study 1395210 — intervention group
Group type: EXPERIMENTAL
Intervention: Causes of death in CHF patients.
Number of subjects: 0
Study 6487508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (conventional therapeutic doses)
Number of subjects: 0
Study 6487508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29772387 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle Angina Questionnaire Summary Score (SAQ SS)
Number of subjects: 4013
Study 29772387 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle Angina Questionnaire Physical Limitation (SAQ PL) scale
Number of subjects: 4013
Study 29772387 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle Angina Questionnaire Anginal Stability (SAQ AS) scores
Number of subjects: 4013
Study 29772387 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle Angina Questionnaire Angina Frequency (SAQ AF) scale
Number of subjects: 4013
Study 29772387 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle Angina Questionnaire Quality of Life (SAQ QoL) scores
Number of subjects: 4013
Study 29772387 — intervention group
Group type: EXPERIMENTAL
Intervention: SAQ scales
Number of subjects: 4013
Study 29772387 — intervention group
Group type: EXPERIMENTAL
Intervention: SAQ SS
Number of subjects: 4013
Study 27314365 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Elderly (HE)
Number of subjects: 305
Study 27314365 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease (AD)
Number of subjects: 305
Study 27314365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI)
Number of subjects: 305
Study 25198487 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 70
Study 25198487 — intervention group
Group type: COMPARATOR
Intervention: No music therapy (Control)
Number of subjects: 70
Study 22718152 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bromfenac
Number of subjects: 38
Study 22718152 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 38
Study 20094704 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program
Number of subjects: 62
Study 20094704 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) program
Number of subjects: 62
Study 18655740 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal inspiration with thoracic support
Number of subjects: 21
Study 18655740 — intervention group
Group type: COMPARATOR
Intervention: Thoracic support alone
Number of subjects: 21
Study 18655740 — intervention group
Group type: COMPARATOR
Intervention: Different cough conditions
Number of subjects: 21
Study 18655740 — intervention group
Group type: COMPARATOR
Intervention: First day versus second measurement day
Number of subjects: 21
Study 15853110 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Cavity conditioner and Fuji II LC (GC America)
Number of subjects: 36
Study 15853110 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Prime & Bond NT and Dyract Flow (Caulk‐Dentsply)
Number of subjects: 36
Study 15853110 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: Excite and Tetric flow (Ivoclar/Vivadent)
Number of subjects: 36
Study 12459926 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 0.25 mg
Number of subjects: 12
Study 12459926 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 0.5 mg
Number of subjects: 12
Study 12459926 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 1 mg
Number of subjects: 12
Study 12459926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10514777 — intervention group
Group type: COMPARATOR
Intervention: Propofol without additives
Number of subjects: 3
Study 10514777 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with 20 mg of lidocaine
Number of subjects: 3
Study 10514777 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with 40 mg of lidocaine
Number of subjects: 3
Study 8673684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg
Number of subjects: 343
Study 8673684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 343
Study 8673684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 343
Study 1932611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 5 mg benzydamine
Number of subjects: 6
Study 1932611 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of benzydamine
Number of subjects: 6
Study 1932611 — intervention group
Group type: COMPARATOR
Intervention: Mouthwash application of benzydamine
Number of subjects: 6
Study 1932611 — intervention group
Group type: COMPARATOR
Intervention: Dermal cream application of benzydamine
Number of subjects: 6
Study 1932611 — intervention group
Group type: COMPARATOR
Intervention: Vaginal douche application of benzydamine
Number of subjects: 6
Study 6588267 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (3 to 5 times weekly for a mean of 12 +/- 4 months)
Number of subjects: 25
Study 6588267 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 25
Study 6588267 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 25
Study 31247033 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive emotions reporting
Number of subjects: 90
Study 31247033 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotions reporting
Number of subjects: 90
Study 31247033 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-emotional internal states reporting
Number of subjects: 90
Study 31247033 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 90
Study 29231343 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding combined with auricular point pressure
Number of subjects: 60
Study 29231343 — intervention group
Group type: COMPARATOR
Intervention: Nilestriol (1 mg once a day) combined with oryzanol (20 mg three times per day)
Number of subjects: 60
Study 26493557 — intervention group
Group type: EXPERIMENTAL
Intervention: PP‐501‐A‐Lidocaine
Number of subjects: 66
Study 26493557 — intervention group
Group type: COMPARATOR
Intervention: RestylaneLidocaine(®)
Number of subjects: 66
Study 24169335 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin (25 mg/kg)
Number of subjects: 50
Study 24169335 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin (50 mg/kg)
Number of subjects: 50
Study 24169335 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin (75 mg/kg)
Number of subjects: 50
Study 24169335 — intervention group
Group type: COMPARATOR
Intervention: IL‐13 control (10 µg/L IL‐13 + physiological saline)
Number of subjects: 50
Study 24169335 — intervention group
Group type: COMPARATOR
Intervention: Negative control (physiological saline)
Number of subjects: 50
Study 24169335 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin (25 µmol/L)
Number of subjects: 50
Study 24169335 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin (50 µmol/L)
Number of subjects: 50
Study 24169335 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin (75 µmol/L)
Number of subjects: 50
Study 21840502 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) procedure inducing bias toward negative material
Number of subjects: 116
Study 21840502 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) procedure inducing bias toward positive material
Number of subjects: 116
Study 21840502 — intervention group
Group type: COMPARATOR
Intervention: Control group (high-expression 5-HTTLPR gene)
Number of subjects: 116
Study 18653640 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles vaccination using standard titre Edmonston‐Zagreb vaccine at 4.5 months of age
Number of subjects: 1333
Study 18653640 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated)
Number of subjects: 1333
Study 18653640 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (vaccinated)
Number of subjects: 1333
Study 16868892 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 or 3.0 mg dexamethasone (DEX) per os at 09:00 or 21:00 hours
Number of subjects: 40
Study 16868892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15305654 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 138
Study 15305654 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 138
Study 15305654 — intervention group
Group type: COMPARATOR
Intervention: Surgery only group
Number of subjects: 138
Study 11718195 — intervention group
Group type: EXPERIMENTAL
Intervention: Plated group
Number of subjects: 50
Study 11718195 — intervention group
Group type: COMPARATOR
Intervention: Non-plated group
Number of subjects: 50
Study 9150772 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of fentanyl (2 micrograms/ml) and bupivacaine (1.0 mg/ml) at a rate of 0.25 ml.kg‐1.h‐1
Number of subjects: 31
Study 9150772 — intervention group
Group type: COMPARATOR
Intervention: Intermittent epidural morphine (30 micrograms/kg every 8 h)
Number of subjects: 31
Study 7957516 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual spray (2.5 mg)
Number of subjects: 16
Study 7957516 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual tablet (5 mg)
Number of subjects: 16
Study 7957516 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral tablet (10 mg)
Number of subjects: 16
Study 7957516 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 16
Study 7957516 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodynamic effects
Number of subjects: 16
Study 3821226 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed educational materials and face-to-face visits by clinical pharmacists (experimental group)
Number of subjects: 435
Study 3821226 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 435
Study 3821226 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up reinforcement visit (experimental group)
Number of subjects: 435
Study 3821226 — intervention group
Group type: EXPERIMENTAL
Intervention: Total exposure time (experimental group)
Number of subjects: 435